(Januaro 2021) “Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial”, The Lancet. Infectious Diseases21 (1), p. 39–51. doi:10.1016/s1473-3099(20)30831-8.
(26a de Majo 2021) “Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial”, JAMA326 (1), p. 35–45. doi:10.1001/jama.2021.8565.
(Septembro 2020) “COVID-19 vaccine trials should seek worthwhile efficacy”, Lancet396 (10253), p. 741–743. doi:10.1016/S0140-6736(20)31821-3. “WHO recommends that successful vaccines should show an estimated risk reduction of at least one-half, with sufficient precision to conclude that the true vaccine efficacy is greater than 30%. This means that the 95% CI for the trial result should exclude efficacy less than 30%. Current US Food and Drug Administration guidance includes this lower limit of 30% as a criterion for vaccine licensure.”.
